Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) Director Chris Anigeron Rallis sold 1,186 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of C$9.68, for a total value of C$11,485.70.
Fennec Pharmaceuticals Price Performance
Shares of FRX stock opened at C$9.80 on Friday. The stock’s 50-day moving average is C$8.91 and its 200 day moving average is C$7.72. Fennec Pharmaceuticals Inc. has a 1-year low of C$5.65 and a 1-year high of C$15.20. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The company has a market cap of C$188.99 million, a P/E ratio of -166.01 and a beta of 0.25.
Analyst Upgrades and Downgrades
Separately, Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Featured Stories
- Five stocks we like better than Fennec Pharmaceuticals
- How to Invest in Small Cap StocksĀ
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- Canadian Penny Stocks: Can They Make You Rich?
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- What is a Stock Market Index and How Do You Use Them?
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.